| Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. | |
| | |
MedLine Citation:
|
PMID: 21138337 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the clinical efficacy and safety of tobramycin/dexamethasone (TobraDex ST ; 'ST') ophthalmic suspension 0.3%/0.05% compared to azithromycin (Azasite) ophthalmic solution (1%) in the treatment of moderate to severe blepharitis/blepharoconjunctivitis. RESEARCH DESIGN AND METHODS: The study was a multicenter, randomized, investigator-masked, and active-controlled, 15-day study. Enrolled in the study were 122 adult subjects (at least 18 years of age) diagnosed with moderate to severe blepharitis/blepharoconjunctivitis, defined by a minimum score of at least '1' for one of the lid signs, one of the conjunctival signs, and one of the symptoms in at least one eye and a minimum global score (total signs and symptoms score) of '5' in the same eye. One group of 61 subjects received ST with instructions to dose 1 drop four times daily (QID) for 14 days. The other group of 61 subjects received azithromycin and dosed with 1 drop twice daily (BID) for 2 days followed by once daily (QD) dosing for 12 days. Visits were conducted at Day 1 (baseline), Day 8 and Day 15. The a priori primary outcome parameter of the study was the seven-item global score defined as the total score of lid margin redness, bulbar conjunctival redness, palpebral conjunctival redness, ocular discharge (0-3 scale), and lid swelling, itchy eyelids, and gritty eyes (0-4 scale). The study utilized standardized, validated photograph control scales developed by Ora, Inc. (Andover, MA). Clinical trial registration: The study was registered at ClinicalTrials.gov under the registry number NCT01102244. RESULTS: A statistically significant lower mean global score (p = 0.0002) was observed in subjects treated with ST compared to subjects treated with azithromycin at Day 8. No serious adverse events were reported during the course of the study in either group. CONCLUSION: ST provides a fast and effective treatment of acute blepharitis compared to azithromycin. Initial therapy with the combination of tobramycin/dexamethasone provides faster inflammation relief than azithromycin for moderate to severe blepharitis/blepharoconjunctivitis. |
| | |
Authors:
|
Gail L Torkildsen; Paul Cockrum; Edward Meier; William M Hammonds; Bruce Silverstein; Steven Silverstein |
Related Documents
:
|
17917937 - Outcomes in randomized controlled trials in psoriasis: what has changed over the last 2... 20846487 - Sodium iodide associated to salicylic acid in the topical management of chronic oral ca... 19210697 - Etanercept: efficacy and safety. 2292327 - Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate... 12905147 - Detection and quantification of mycoplasma genitalium in male patients with urethritis. 6595937 - Hereditary diffuse leucoencephalopathy with spheroids. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-12-07 |
Journal Detail:
|
Title: Current medical research and opinion Volume: 27 ISSN: 1473-4877 ISO Abbreviation: Curr Med Res Opin Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0351014 Medline TA: Curr Med Res Opin Country: England |
Other Details:
|
Languages: eng Pagination: 171-8 Citation Subset: IM |
Affiliation:
|
Andover Eye Associates, Andover, MA 01810, USA. mdlasik@comcast.net |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT01102244 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment init...
Next Document: Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analy...